Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- Forest Investigative Site #050
-
Vancouver, British Columbia, Canada, V6Z 2L4
- Forest Investigative Site #051
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1S 2E8
- Forest Investigative Site #052
-
-
Ontario
-
Chatham, Ontario, Canada, N7M 1B7
- Forest Investigative Site #055
-
Ottawa, Ontario, Canada, K1G 4G3
- Forest Investigative Site #053
-
-
-
-
California
-
Beverly Hills, California, United States, 90210
- Forest Investigative Site #023
-
Encino, California, United States, 31316
- Forest Investigative Site #017
-
Garden Grove, California, United States, 92845
- Forest Investigative Site #021
-
Newport Beach, California, United States, 92660
- Forest Investigative Site #025
-
Orange, California, United States, 92868
- Forest Investigative Site #030
-
San Diego, California, United States, 92108
- Forest Investigative Site #002
-
Sherman Oaks, California, United States, 91403
- Forest Investigative Site #003
-
-
Florida
-
Bonita Springs, Florida, United States, 34134
- Forest Research Institute #001
-
Fort Myers, Florida, United States, 33912
- Forest Investigative Site #015
-
Maitland, Florida, United States, 32751
- Forest Investigative Site #029
-
North Miami, Florida, United States, 33161
- Forest Investigative Site #005
-
Orlando, Florida, United States, 32806
- Forest Investigative Site #016
-
South Miami, Florida, United States, 33143
- Forest Investigative Site #004
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Forest Investigative Site #014
-
-
Illinois
-
Chicago, Illinois, United States, 60634
- Forest Investigative Site #022
-
Chicago, Illinois, United States, 60640
- Forest Investigative Site #006
-
-
Kansas
-
Prairie Village, Kansas, United States, 66206
- Forest Investigative Site #009
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
- Forest Investigative Site #013
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02135
- Forest Investigative Site #010
-
-
Missouri
-
Saint Louis, Missouri, United States, 63139
- Forest Investigative Site #012
-
-
New York
-
Staten Island, New York, United States, 10312
- Forest Investigative Site #011
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Forest Investigative Site #026
-
-
Pennsylvania
-
Bridgeville, Pennsylvania, United States, 15017
- Forest Investigative Site #008
-
Norristown, Pennsylvania, United States, 19401
- Forest Investigative Site #028
-
Philadelphia, Pennsylvania, United States, 19139
- Forest Investigative Site #020
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Forest Investigative Site #024
-
-
Texas
-
Dallas, Texas, United States, 75231
- Forest Investigative Site #007
-
San Antonio, Texas, United States, 78229
- Forest Investigative Site #019
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Forest Investigative Site #018
-
Seattle, Washington, United States, 98104
- Forest Investigative Site #027
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, 18-65 years old
- Currently meet the DSM-IV-TR criteria for Major Depressive Disorder
- The patient's current depressive episode must be at least 4 weeks in duration
Exclusion Criteria:
- Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control
Patients with a history of meeting DSM-IV-TR criteria for:
- any manic or hypomanic episode
- schizophrenia or any other psychotic disorder
- obsessive-compulsive disorder
- Patients who are considered a suicide risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 2
40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
|
Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
|
|
Placebo Comparator: 1
Matching placebo capsules, oral administration, once daily dosing.
|
Matching placebo to be given orally, in capsule form, once daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Relapse (Days)
Time Frame: 24 Weeks
|
Number of days until patients meet relapse criteria.
Relapse was defined as 1 or more of the following: 1. MADRS total score of at least 22 at 2 consecutive visits 2. Increase of 2 or more points in CGI-I score compared with the CGI-I score at Visit 9 at 2 consecutive visits 3. Premature discontinuation due to insufficient therapeutic response 4. MADRS item 10 score of at least 4
|
24 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Milnacipran
- Levomilnacipran
Other Study ID Numbers
Other Study ID Numbers
- LVM-MD-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.